# Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke

Study · id `cardio:ct-nct04950920` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04950920](<https://clinicaltrials.gov/study/NCT04950920>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04950920

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 914 participants.

## Technical summary

Registry record NCT04950920. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-28 (actual); primary completion 2022-08-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 914 participants (enrolled count; ClinicalTrials.gov record NCT04950920, source copy `cardio:ctgov-nct04950920-2023-08-22`, retrieved 2026-10-26)
- Started: 2021-06-28 (actual) (ClinicalTrials.gov record NCT04950920, source copy `cardio:ctgov-nct04950920-2023-08-22`, retrieved 2026-10-26)
- Primary completion: 2022-08-10 (actual) (ClinicalTrials.gov record NCT04950920, source copy `cardio:ctgov-nct04950920-2023-08-22`, retrieved 2026-10-26)
- Completion: 2022-11-14 (actual) (ClinicalTrials.gov record NCT04950920, source copy `cardio:ctgov-nct04950920-2023-08-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04950920, source copy `cardio:ctgov-nct04950920-2023-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04950920-2023-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke
- Condition: Stroke
- Intervention (Drug): Y-2 sublingual tablets
- Intervention (Drug): d-borneol
- Lead sponsor: Peking University Third Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Peking University Third Hospital (`cardio:org-peking-university-third-hospital`)

## Provenance

Content hash: 0adfeb93bb3dd1bf001fda911468ff3d61124509ce82ff94f99e5eacc965deb6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
